Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 2,079 shares, a decrease of 91.2% from the November 30th total of 23,686 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 16,661 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily volume of 16,661 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s shares are short sold.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ATHE. Greenleaf Trust bought a new position in shares of Alterity Therapeutics during the 2nd quarter worth approximately $70,000. Twin Lakes Capital Management LLC increased its position in shares of Alterity Therapeutics by 2,250.3% during the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after acquiring an additional 133,333 shares during the last quarter. HB Wealth Management LLC bought a new stake in Alterity Therapeutics during the third quarter worth $220,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Alterity Therapeutics during the 3rd quarter valued at $83,000. 2.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Wednesday, October 8th. Canaccord Genuity Group started coverage on Alterity Therapeutics in a research note on Wednesday, December 17th. They set a “speculative buy” rating for the company. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $12.00.

Alterity Therapeutics Trading Down 1.9%

Shares of ATHE traded down $0.06 on Wednesday, reaching $3.03. The company’s stock had a trading volume of 12,173 shares, compared to its average volume of 167,254. Alterity Therapeutics has a twelve month low of $2.46 and a twelve month high of $7.00. The firm has a fifty day moving average of $3.78 and a 200-day moving average of $4.37.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.